



## SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)

(Company Registration Number: 201134046D)

---

### ENTRY INTO MEDICAL SERVICES AGREEMENT BETWEEN WHOLLY-OWNED SUBSIDIARY AND ICON SOC PTE. LTD.

---

The Board of Directors (the “**Board**” or “**Directors**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to announce that Proton Therapy Pte. Ltd. (“**PTPL**”), a wholly-owned subsidiary of the Company, has on 26 June 2024 entered into an agreement with Icon SOC Pte. Ltd. (“**Icon**”), pursuant to which Icon will appoint PTPL to provide proton therapy treatment medical services to Icon’s patients, in accordance with the terms and conditions therein (“**Medical Services Agreement**”).

Icon is a private company incorporated in Singapore, and is primarily engaged in the business of the provision of oncology services including medical oncology, haematology, radiation oncology, paediatric oncology, PET-CT (Positron emission tomography–computed tomography) and research to deliver an integrated, end-to-end seamless service for cancer patients.

Under the Medical Services Agreement, Icon will coordinate with PTPL to provide proton therapy treatment to Icon’s patients. Icon will reimburse PTPL for such services based on an agreed upon fee schedule for such referrals for medical services by Icon. The Medical Services Agreement will commence from 1 July 2024 for an initial term of 3 years, and may be renewed thereafter or otherwise terminated by either party at any time by written notice of at least 6 months to the other party.

None of the Directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect, in the Medical Services Agreement, other than through their respective shareholdings (if any), employment and/or directorship (as applicable) in the Company.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien  
Executive Director and Chief Executive Officer  
26 June 2024

---

Singapore Institute of Advanced Medicine Holdings Ltd. (the “Company”) was listed on Catalist of the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”).

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg).